Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Transaction in Own Shares

20th Sep 2013 07:00

SHIRE PLC - Transaction in Own Shares

SHIRE PLC - Transaction in Own Shares

PR Newswire

London, September 19

Transaction in Own Shares September 20, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")announces that, in accordance with the authority granted by shareholders at theCompany's Annual General Meeting on April 30, 2013, it purchased 3,896 of itsordinary shares of 5 pence each ("Ordinary Shares") on September 19, 2013through both direct purchases of Ordinary Shares, and through the purchase ofOrdinary Shares underlying ADRs. The highest and lowest price paid for thedirectly acquired Ordinary Shares was 2548.00 pence per share and 2535.00 penceper share respectively, and for those Ordinary Shares acquired though thepurchase of ADRs was 4091.33 cents per share and 4078.67 cents per sharerespectively. The purchased shares will be held as treasury shares. Following the abovepurchase, the Company holds 9,723,202 Ordinary Shares as treasury shares andhas 553,174,161 Ordinary Shares in issue (excluding treasury shares). The purchases were made by an independent third party which makes its tradingdecisions independently of, and uninfluenced by, the Company. The independenceof the third party enables the Company to continue to purchase Ordinary Shares(including Ordinary Shares underlying ADRs) during close periods and otherprohibited periods, should they arise. The third party has been appointed bythe Company to make purchases to December 31, 2013. For further information please contact: Investor Relations Eric Rojas [email protected] +1 781 482 0999 Sarah Elton-Farr [email protected] +44 1256 894157 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,Internal Medicine and Regenerative Medicine and we are developing treatmentsfor symptomatic conditions treated by specialist physicians in other targetedtherapeutic areas. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com

Related Shares:

Shire
FTSE 100 Latest
Value8,774.65
Change-17.15